Radiation plus immune therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT07528352
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing whether giving radiation therapy before a bispecific antibody drug (either epcoritamab or glofitamab) is safe and feasible for people with relapsed or refractory diffuse large B-cell lymphoma. The study will enroll 12 adults who have already tried at least two prior treatments. The main goal is to see if this combination keeps serious side effects like cytokine release syndrome and neurological problems at acceptable levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Epcoritamab or Glofitamab (bispecific antibodies) plus external beam radiation therapy
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with hard-to-treat diffuse large B-cell lymphoma who have run out of standard therapies.
- What could go wrong
- This is a very early, small Phase 1b trial with only 12 participants, so results may not apply broadly. The main risks are serious side effects like cytokine release syndrome and neurological toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute at University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?